Polar Capital Holdings Plc Acquires New Shares in Oruka Therapeutics, Inc. (NASDAQ:ORKA)

Polar Capital Holdings Plc bought a new stake in Oruka Therapeutics, Inc. (NASDAQ:ORKA - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 550,000 shares of the company's stock, valued at approximately $10,664,000. Polar Capital Holdings Plc owned approximately 1.57% of Oruka Therapeutics as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. Paradigm Biocapital Advisors LP raised its holdings in Oruka Therapeutics by 13.9% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 819,660 shares of the company's stock valued at $15,893,000 after acquiring an additional 100,000 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new stake in Oruka Therapeutics during the fourth quarter worth approximately $384,000. Millennium Management LLC acquired a new stake in Oruka Therapeutics during the fourth quarter worth approximately $588,000. Janus Henderson Group PLC raised its holdings in Oruka Therapeutics by 259.7% during the fourth quarter. Janus Henderson Group PLC now owns 849,410 shares of the company's stock worth $16,415,000 after purchasing an additional 613,294 shares in the last quarter. Finally, Jefferies Financial Group Inc. acquired a new stake in Oruka Therapeutics during the fourth quarter worth approximately $6,787,000. Institutional investors and hedge funds own 56.44% of the company's stock.

Analyst Ratings Changes

ORKA has been the topic of a number of research analyst reports. Wolfe Research assumed coverage on shares of Oruka Therapeutics in a report on Tuesday, February 4th. They set an "outperform" rating and a $20.00 price objective on the stock. HC Wainwright reissued a "buy" rating and issued a $45.00 target price on shares of Oruka Therapeutics in a report on Friday, February 7th. Finally, Wedbush reissued an "outperform" rating and issued a $40.00 target price on shares of Oruka Therapeutics in a report on Thursday, May 15th. Seven investment analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $39.86.

Oruka Therapeutics Stock Up 2.7%

NASDAQ ORKA traded up $0.29 during trading hours on Wednesday, hitting $10.91. The company had a trading volume of 39,882 shares, compared to its average volume of 226,138. Oruka Therapeutics, Inc. has a fifty-two week low of $5.49 and a fifty-two week high of $31.13. The business has a fifty day simple moving average of $9.83 and a 200-day simple moving average of $14.54. The firm has a market cap of $408.48 million, a P/E ratio of -1.74 and a beta of 0.25.

Oruka Therapeutics (NASDAQ:ORKA - Get Free Report) last issued its earnings results on Wednesday, May 14th. The company reported ($0.40) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.17. Equities analysts forecast that Oruka Therapeutics, Inc. will post -3.41 EPS for the current fiscal year.

Oruka Therapeutics Profile

Oruka Therapeutics, Inc is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.